Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors

Journal of the American Academy of Dermatology

Volumn 56, Issue 5, 2007, Pages 848-853

  Krasowska, Dorota ^a   Szymanek, Magdalena ^a   Schwartz, Robert A ^c   Myśliński, Wojciech ^b  

^a Departments of Dermatology   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN;

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALOPECIA; ANGIONEUROTIC EDEMA; ANXIETY CRISIS; ANXIETY DISORDER; BLEEDING; BLEEDING INTERNAL HEMORRHOID; BLEEDING TIME; BODY DYSMORPHIC DISORDER; BRADYCARDIA; BREAST CANCER; BRUXISM; CROSS REACTION; DELUSION; DELUSION OF PARASITE; DEPRESSION; DRUG EFFECT; DRUG SAFETY; ECCHYMOSIS; EPISTAXIS; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HAIR DISEASE; HAIR HYPERPIGMENTATION; HAIR LOSS; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HEMORRHOID; HIGH RISK POPULATION; HIRSUTISM; HUMAN; HYPERHIDROSIS; HYPERPIGMENTATION; HYPERTRICHOSIS; INAPPROPRIATE VASOPRESSIN SECRETION; LEUKOCYTOCLASTIC VASCULITIS; MELENA; MENORRHAGIA; METRORRHAGIA; MIGRAINE; NAIL DISEASE; NAIL HYPERPIGMENTATION; NEUROSIS; NEUROTIC EXCORIATION; NOCTURNAL BRUXISM; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PETECHIA; PHOTOALLERGY; PHOTOTOXICITY; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; PSORIASIS; PSYCHOCUTANEOUS DISEASE; PUSTULOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROTONIN SYNDROME; SKIN BRUISING; SKIN DISEASE; SPLENOMEGALY; SPONTANEOUS BLEEDING; SPONTANEOUS BRUISING; STEVENS JOHNSON SYNDROME; STUTTERING; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; ULCER; URTICARIA; VAGINA BLEEDING;

ANTIDEPRESSIVE AGENTS; HUMANS; SEROTONIN UPTAKE INHIBITORS; SKIN DISEASES;

EID: 34147099029     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.10.020     Document Type: Review

References (64)

1. Green B. Focus on paroxetine. Curr Med Res Opin 19 (2003) 13-21
2. Serebruany V.L. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med 119 (2006) 113-116
3. Warnock J.K., and Morris D.W. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 3 (2002) 329-339
4. Wernicke J.F. The side effect profile and safety of fluoxetine. J Clin Psychiatry 46 (1985) 59-67
5. Pai V.B., and Kelly M.W. Bruising associated with the use of fluoxetine. Ann Pharmacother 30 (1996) 786-788
6. Cooper T.A., Valcour V.G., Gibbons R.B., and O'Brien-Falls K. Spontaneous ecchymoses due to paroxetine administration. Am J Med 104 (1998) 197-198
7. Morgolese H.C., Chouinard G., Beauclair L., and Rubino M. Cutaneous vasculitis induced by paroxetine. Am J Psychiatry 158 (2001) 497
8. Aranth J., and Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry 149 (1992) 412
9. Maistre E., Allart C., Lecompte T., and Bollaert P.E. Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors. Am J Med 113 (2002) 530-532
10. Yaryura-Tobias J.A., Kirshen H., Ninan P., and Mosberg H.J. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry 148 (1991) 949
11. Skop B., and Brown T. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 37 (1996) 12-16
12. Oyesanmi O., Kunkel E.J.S., Monti D.A., and Field H.L. Hematologic side effects of psychotropics. Psychosomatics 40 (1999) 414-421
13. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 62 (2005) 159-170
14. Warnock J.K., and Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 145 (1988) 425-430
15. Cooper G.L. The safety of fluoxetine-an update. Br J Psychiatry 153 (1988) 77-86
16. Leznof A., Binkley K.E., Joffee R.T., Levitt A., and Richter M.A. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. J Clin Psychopharmacol 12 (1992) 355-357
17. Jan V., Toledano C., Machet L., Machet M.C., Vaillant L., and Lorette G. Stevens-Johnson syndrome after sertaline. Acta Derm Venereol 42 (2000) 287
18. Bodokh I., Lacour J.P., and Rosenthal E. Toxic epidermal necrolysis and Stevens-Johnson syndrome after fluoxetine. Therapie 47 (1992) 441
19. Vincent A., Douville M., and Baruch P. Serum sickness induced by fluoxetine. Am J Psychiatry 148 (1991) 1602-1603
20. Wolkenstein P., Renuz J., and Diehl J.L. Toxic epidermal necrolysis after fluvoxamine. Lancet 342 (1993) 304-305
21. Richard M.A., Fiszenson F., Jreissati M., Pastor M.J., and Grob J.J. Cutaneous adverse effects during selective serotonin inhibitor therapy: 2 cases. Ann Dermatol Venereol 128 (2001) 759-761
22. Beauquier B., and Fahs H. Secondary dermatologic effects of serotonin reuptake inhibitor antidepressants: hypothesis of cross-reacting allergy; apropos of 2 cases. Encephale 24 (1998) 62-64
23. Warnock C.A., and Azadian A.G. Cross-sensitivity between paroxetine and sertraline. Ann Pharmacother 36 (2002) 631-633
24. Mithani H., and Hurwitz T.A. Paroxetine-induced angioedema and tongue swelling. J Clin Psychiatry 57 (1996) 486
25. Thédenat B., Loche F., Albes B., Marguery M.C., and Bazex J. Acute generalized exanthematous pustulosis with photodistribution pattern induced by sertraline. Dermatology 203 (2001) 87-88
26. Rebora A. Changes in growth and distribution of hair associated with psychotropic drug use. CNS Drugs 8 (1977) 323-334
27. Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry 153 (1996) 581-582
28. Zalsman G., Sever J., and Munitz H. Hair loss associated with paroxetine treatment: a case report. Clin Neuropharmacol 22 (1999) 246-247
29. Ananth J., and Elmishaugh A. Hair loss associated with fluoxetine treatment. Can J Psychiatry 36 (1991) 621
30. Umansky L., Dorevitch A., and Sella A. Alopecia due to Seroxat. Harefuah 138 (2000) 547-549 614
31. Hemlock C., Rosenthal J.S., and Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 26 (1992) 211-212
32. Osborne S.F., Stafford L., and Orr K.G.D. Paroxetine-associated psoriasis. Am J Psychiatry 159 (2002) 2113
33. Vilaplana J., Botey E., Lecha M., Herrero C., and Romaguera C. Photosensivity induced by paroxetine. Contact Dermatitis 47 (2002) 118-119
34. Pazzagli L., Banfi R., Borselli G., and Semmola M.V. Photosensitivity reaction to fluoxetine and alprazolam. Pharm World Sci 20 (1998) 136
35. Gaufberg E., and Ellison J.M. Photosensitivity reaction of fluoxetine. J Clin Psychiatry 56 (1995) 486
36. Gillet-Terver M.N., Modiano P., Trechot P., Barbaud A., and Schmutz J.L. Fluvoxamine photosensivity. Australas J Dermatol 37 (1996) 62
37. Mazzatenta C., Peonia G., and Martini P. Pruritus induced by interruption of paroxetine therapy. Br J Dermatol 150 (2004) 787-788
38. Biondi M., Arcangeli T., and Petrucci R.M. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 69 (2000) 165-166
39. Zylicz Z., and Krajnik M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 26 (2003) 1105-1112
40. Schwartz RA, Patterson WM, Bienvenu OJ, Chodynicki MP, Janniger CK. Dysmorphophobia. eMedicine Dermatology [journal serial online]. 2006. Available from: http://www.emedicine.com/derm/topic623.htm. Accessed July 26, 2006.
41. Thomas I., Patterson W.M., Szepietowski J., Chodynicki M.P., Janniger C.K., Hendel P.M., et al. Body dysmorphic disorder: more than meets the eye. Acta Derm Venerol Croatica 13 (2005) 44-49
42. Hoss D., and Segal S. Scalp dysthesia. Arch Dermatol 134 (1998) 327-330
43. Egberts A.C., Meyboom R.H., De Koning F.H., Bakker A., and Leufkens HG. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 44 (1997) 277-281
44. Peterson M.C. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76 (2001) 215-216
45. Choo V. Paroxetine and extrapyramidal reactions. Lancet 341 (1993) 624
46. Arya D. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 165 (1994) 728-733
47. Mendel J. Clinical experience with serotonin reuptake inhibiting antidepressants. J Clin Psychiatry 48 (1987) 26-30
48. Guthrie S., and Grunhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry 51 (1990) 85
49. McCall W. Sertraline-induced stuttering. J Clin Psychiatry 55 (1994) 316
50. Ellison J., and Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 54 (1993) 432-434
51. Romanelli F., Adler D.A., and Bungay K.M. Possible paroxetine-induced bruxism. Ann Pharmacother 30 (1996) 1246-1248
52. Blackstern J., and Birt J. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 27 (1993) 273-274
53. Jackson C., Carson W., Markowitz J., and Mintzer J. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry 152 (1995) 809-810
54. Roose J. Cardiac effects of antidepressant drugs: a comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 15 (1983) 4395-4455
55. Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry 52 (1991) 139
56. Drake W., and Gordon G. Heart block in a patient on propranolol and fluoxetine. Lancet 343 (1994) 425-426
57. Feighner J., Boyer W., and Tyler D. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 51 (1990) 222-225
58. Steiner W., and Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five cases reports. Biol Psychiatry 21 (1986) 1067-1071
59. Sternbach H. The serotonin syndrome. Am J Psychiatry 148 (1991) 705-713
60. Lerner U.H. Serotonin reuptake inhibitors may increase the risk of osteoporosis. Lakartidningen 102 (2005) 2746-2749
61. Landy S., McGinnis J., Curlin D., and Laizure S.C. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 39 (1999) 28-32
62. Bickel A., Kornhuber J., Maihofner C., and Ropohl A. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline: a case report. Pharmacopsychiatry 38 (2005) 327-328
63. Moorman P.G., Grubber J.M., Millikan R.C., and Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14 (2003) 307-314
64. Wallace W.A., Balsitis M., and Harrison B.J. Male breast neoplasia in association with selective serotonin re-uptake inhibitor therapy: a report of three cases. Eur J Surg Oncol 27 (2001) 429-431